Get In Touch

Nivolumab Drugs Market: Introduction

  • Nivolumab is a targeted therapy drug and the generic name of Opdivo. Currently, nivolumab has received approval for various indications such as unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), advanced renal cell cancer, classical Hodgkin’s lymphoma (cHL), and recurrent or metastatic squamous cell carcinoma.
  • It is administered intravenously every two weeks. The amount of nivolumab administered depends on various factors such as type of condition and general health of the patient.

Key Drivers, Restrains, and Opportunities of Global Nivolumab Drugs Market

  • Higher incidence of non-small cell lung cancer (NSCLC) is expected to drive the nivolumab drugs market during the forecast period. According to the American Cancer Society’s estimates, approximately 235,760 new cases were diagnosed and 131,880 person died from lung cancer in 2020, in the U.S. In general, about 84% lung cancer cases are non-small cell lung cancer (NSCLC).
  • Approval of nivolumab for newer indications is also anticipated to further boost the market during the forecast period. For instance, on January 22, 2021, USFDA approved a combination of cabozantinib and nivolumab for the treatment of advanced renal cell carcinoma.

North America to Capture Major Share of Global Nivolumab Drugs Market

  • North America is expected to account for a major share of the global nivolumab drugs market due to higher incidence of advanced renal cell carcinoma, classical Hodgkin’s lymphoma (cHL), and recurrent or metastatic squamous cell carcinoma in the region. Moreover, high disposable income and increasing healthcare expenditure are anticipated to drive the market in the region.
  • The nivolumab drugs market in Asia Pacific is projected to expand at a rapid pace during the forecast period owing to a rise in the prevalence of metastatic non-small cell lung cancer (NSCLC) in the region

Key Players Operating in Global Nivolumab Drugs Market

Nivolumab is a patented drug under the brand Opdivo

Major players operating in the global nivolumab drugs market are listed below:

  • Bristol-Myers Squibb Company

Global Nivolumab Drugs Market: Research Scope

Global Nivolumab Drugs Market, by Strength

  • 40 mg/4 mL
  • 100 mg/10 mL
  • 240 mg/24 mL

Global Nivolumab Drugs Market, by Indication

  • Non-Small Cell Lung Cancer (NSCLC)
  • Melanoma
  • Malignant Pleural Mesothelioma
  • Renal Cell Carcinoma (RCC)
  • Classical Hodgkin Lymphoma (cHL)
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • Others

Global Nivolumab Drugs Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Nivolumab Drugs Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Nivolumab Drugs Market